急性肾损伤管理:2018核心课程
急性肾损伤(AKI)是住院患者常见的异质性疾病,与短期和长期发病率及死亡率相关。应迅速查明可逆病因,优化容量状态并避免肾毒性药物,晶体液优于胶体液,避免羟乙基淀粉。目前无靶向药物获批,重症患者肾脏替代治疗最佳时机尚不明确,近期研究提示AKI与慢性肾脏病、后续AKI及未来死亡风险增加密切相关。
要点
- AKI需迅速排查可逆病因,优化容量状态并避免肾毒性药物。
- 多数患者首选晶体液而非胶体液,应避免羟乙基淀粉。
- AKI与慢性肾脏病、后续AKI及远期死亡风险增加相关。
核心结论
- AKI不是自限性过程,与慢性肾脏病、后续AKI及未来死亡风险增加密切相关。
主要发现
- AKI是住院患者常见的异质性疾病,与短期和长期发病率及死亡率相关。
- 容量超负荷与不良结局相关,需关注整体液体平衡。
- 目前无靶向药物获批用于AKI治疗。
- 重症AKI患者肾脏替代治疗的最佳时机尚不明确,是活跃研究领域。
关键数值与推荐
- 预防AKI措施包括优化容量状态和避免肾毒性药物。
- 多数患者晶体液优于胶体液,应避免羟乙基淀粉。
临床怎么用
- 对AKI患者应迅速排查可逆病因,优化容量状态并避免肾毒性药物。
- 多数患者使用晶体液而非胶体液,避免羟乙基淀粉。
- 关注AKI患者整体液体平衡,避免容量超负荷。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute kidney injury (AKI) is a heterogeneous disorder that is common in hospitalized patients and associated with short- and long-term morbidity and mortality. When AKI is present, prompt workup of the underlying cause should be pursued, with specific attention to reversible causes. Measures to prevent AKI include optimization of volume status and avoidance of nephrotoxic medications. Crystalloids are preferred over colloids for most patients, and hydroxyethyl starches should be avoided. Volume overload in the setting of AKI is associated with adverse outcomes, so attention should be paid to overall fluid balance. Currently there are no targeted pharmacotherapies approved for the treatment of AKI. The optimal timing of renal replacement therapy in critically ill patients with AKI is unclear, but is an area of active investigation. Recent studies suggest that AKI is not a "self-limited" process, but is strongly linked to increased risk for chronic kidney disease, subsequent AKI, and future mortality.
引用
- Moore PK, Hsu RK, Liu KD, et al. Management of Acute Kidney Injury: Core Curriculum 2018. Am J Kidney Dis. 2018. PMID: 29478864. doi:10.1053/j.ajkd.2017.11.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。